Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-30

FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Supplemental Application (Apotex Corp.)

View source ↗

Summary

FDA approved a supplemental application for lisdexamfetamine dimesylate by Apotex Corp., approving a generic product under the supplemental filing process.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

SUPPL AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)